CRIS Current Research Information System

LEMOLI, ROBERTO MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.554
AS - Asia 5.136
EU - Europa 3.709
SA - Sud America 297
AF - Africa 270
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 9
Totale 15.993
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.463
VN - Vietnam 1.473
SG - Singapore 1.320
CN - Cina 1.251
GB - Regno Unito 888
SE - Svezia 562
IT - Italia 521
DE - Germania 451
HK - Hong Kong 311
FR - Francia 253
IN - India 242
BR - Brasile 212
UA - Ucraina 178
RU - Federazione Russa 173
IE - Irlanda 153
NL - Olanda 133
JP - Giappone 88
ZA - Sudafrica 88
FI - Finlandia 85
KR - Corea 79
TG - Togo 69
BD - Bangladesh 66
JO - Giordania 64
BG - Bulgaria 57
EE - Estonia 56
CH - Svizzera 55
CA - Canada 54
CI - Costa d'Avorio 48
BE - Belgio 40
AR - Argentina 32
PH - Filippine 32
ID - Indonesia 26
SC - Seychelles 24
TH - Thailandia 24
TR - Turchia 24
TW - Taiwan 24
IR - Iran 23
ES - Italia 20
MX - Messico 19
IQ - Iraq 18
PL - Polonia 18
EU - Europa 17
AT - Austria 14
MY - Malesia 14
CO - Colombia 12
GR - Grecia 12
PY - Paraguay 12
EC - Ecuador 10
AU - Australia 9
CZ - Repubblica Ceca 9
SA - Arabia Saudita 9
NG - Nigeria 8
CL - Cile 7
LB - Libano 7
MA - Marocco 7
UZ - Uzbekistan 7
CR - Costa Rica 6
EG - Egitto 6
AZ - Azerbaigian 5
PE - Perù 5
HR - Croazia 4
JM - Giamaica 4
KG - Kirghizistan 4
PT - Portogallo 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
DZ - Algeria 3
ET - Etiopia 3
HU - Ungheria 3
IL - Israele 3
KZ - Kazakistan 3
LT - Lituania 3
NI - Nicaragua 3
NP - Nepal 3
PK - Pakistan 3
AL - Albania 2
BO - Bolivia 2
BW - Botswana 2
IS - Islanda 2
KW - Kuwait 2
OM - Oman 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
SI - Slovenia 2
UY - Uruguay 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
CM - Camerun 1
GD - Grenada 1
GH - Ghana 1
GI - Gibilterra 1
GT - Guatemala 1
IM - Isola di Man 1
KE - Kenya 1
KH - Cambogia 1
LI - Liechtenstein 1
LY - Libia 1
MD - Moldavia 1
Totale 15.980
Salva come PNG Salva come JPEG
Città #
Singapore 902
Southend 752
Ashburn 714
Fairfield 640
Chandler 531
Houston 455
San Jose 379
Ho Chi Minh City 353
Hanoi 303
Woodbridge 302
Hong Kong 283
Seattle 264
Wilmington 240
Ann Arbor 236
Santa Clara 218
Cambridge 202
Princeton 190
Beijing 183
Hefei 165
Dublin 151
Dong Ket 134
Boardman 125
Jacksonville 108
New York 94
Lauterbourg 89
Los Angeles 87
Tokyo 77
Bologna 76
Westminster 75
Nanjing 72
Helsinki 69
Lomé 69
Padova 68
Amman 64
Haiphong 61
Seoul 61
Buffalo 56
Sofia 54
Council Bluffs 51
Abidjan 48
Jinan 46
Bern 45
Bremen 45
Berlin 43
Da Nang 43
Shenyang 43
Dallas 42
Guangzhou 42
San Diego 42
Brussels 38
Frankfurt am Main 37
Milan 36
Hyderabad 34
Saint Petersburg 34
Turin 33
Tianjin 32
São Paulo 31
Munich 30
Redmond 27
Redondo Beach 26
Shanghai 25
Changsha 23
Biên Hòa 22
Jiaxing 22
London 22
Zhengzhou 22
Mülheim 21
Hebei 20
Orem 20
Florence 19
Phoenix 19
Chicago 18
Johannesburg 18
Nanchang 18
Toronto 18
Norwalk 17
Rome 17
Quận Bình Thạnh 16
Hải Dương 15
Can Tho 14
Bangkok 13
Dearborn 13
Mahé 13
Medford 13
Brooklyn 12
Ha Long 12
Hangzhou 12
Kuala Lumpur 12
Taiyuan 12
Amsterdam 11
Boston 11
Ninh Bình 11
San Francisco 11
Bengaluru 10
Des Moines 10
Falls Church 10
Ningbo 10
Paris 10
Verona 10
Wuhan 10
Totale 10.362
Salva come PNG Salva come JPEG
Nome #
Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection. 372
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 311
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 287
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 271
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 259
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 255
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 238
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 232
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 227
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 226
A novel model of CCl4-induced cirrosi with ascites in the mouse. 225
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 214
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 214
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 213
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 212
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 212
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 211
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 209
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 209
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. 207
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 201
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 200
Platelet lysate enhances the therapeutic activity of Adipose Derived Mesenchymal stromal cells isolated from Crohn disease patients in a novel Mouse model of Colitis 198
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 197
BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study. 194
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 190
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 189
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 188
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 188
Stem cell mobilization and collection in patients with liver cirrhosis. 186
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response 186
Dendritic cell differentiation. 183
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 182
Extracellular ATP exerts opposite effects on activated and regulatory CD4 + T cells via purinergic P2 receptor activation 181
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 181
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 180
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 180
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 180
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 180
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 177
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 174
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. 172
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. 172
Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages. 172
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 172
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 171
Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. 169
Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. 168
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. 166
CD 133+ stem cells for the treatment of end stage liver disease. 163
Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. 161
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 159
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 157
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 157
Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors. 156
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 155
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 154
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 153
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 153
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 152
Hematopoietic stem cell mobilization. 152
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 152
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 150
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engrftment. 149
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product 148
European Data on Stem Cell Mobilization with Plerixafor in Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Multiple Myeloma Patients. A Subgroup Analysis of the European Consortium of Stem Cell Mobilization. 142
Stem cell plasticity: time for a reappraisal ? 141
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 141
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 139
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 137
More ADO about IDO: GVHD. 136
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 134
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 131
The sixth sense: Hematopoietic Stem Cells detect danger through purinergic signalling. 125
The CD47 pathway is deregulated in human immune thrombocytopenia 123
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 118
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. 115
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 115
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. 112
Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. 110
CD133+ hematopoietic stem cells reinfusion in end-stage liver disease (ESLD): final results of a phase I clinical trial 107
Zoledronic acid modulates function and differentiation of myeloid cells. 104
New strategies for stem cell mobilization 101
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 100
The P2X7 receptor: a new player in IL-1 processing and release 99
Granulocyte colony-stimulating factor promotes the generation of regulatory DCs through induction of IL-10 and IFN-alfa. 98
Pegfilgrastim for mobilization of stem cells in allogeneic donors. 98
null 97
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 97
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 95
Pre-emptive use of Plerixafor in hard-to-mobilize patients: An emerging concept. 92
Reinfusion of highly purified CD133+ stem cells in patients with end-stage liver disease (ESLD): final results of a phase I clinical trial 88
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 88
Erratum: Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients (Haematologica (2005) 90, (225-231). 82
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation 66
Evaluation of immunotoxins containing single-chain ribosome- inactivating proteins and an anti-CD22 monoclonal antibody (OM124): In vitro and in vivo studies 59
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation 58
Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation 56
Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: In vitro results and in vivo effects in an acute rejection model 55
In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins 51
Totale 16.162
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.561
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.561
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.777 135 79 103 180 141 100 48 123 54 163 339 312
2022/20232.020 257 289 107 266 120 166 65 92 348 52 138 120
2023/2024545 45 79 42 77 58 130 34 22 7 21 12 18
2024/20251.946 85 306 163 210 327 98 98 49 20 167 75 348
2025/20265.345 517 513 412 387 544 260 496 286 1.155 436 174 165
2026/202778 78 0 0 0 0 0 0 0 0 0 0 0
Totale 16.220